Disease · MONDO_0015691
hypereosinophilic syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hypereosinophilic syndrome. Diseases, record MONDO_0015691. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015691
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- HES, Idiopathic Hypereosinophilic Syndrome, Loeffler Endocarditis, Loeffler's Endocarditis, hypereosinophilic disease, hypereosinophilic disorder
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 11 drugs, from DailyMed and EMA Human Drugs
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| MEPOLIZUMAB | CHEMBL2108429 | Antibody | Approval | DailyMed | 9 | 7 | 7 | Drugs and targets |
| IMATINIB | CHEMBL941 | Small molecule | Approval | EMA Human Drugs | 8 | 2 | 2 | Drugs and targets |
| BENRALIZUMAB | CHEMBL1742991 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DEPEMOKIMAB | CHEMBL4650469 | Antibody | Phase 3 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| IMATINIB MESYLATE | CHEMBL1642 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| RUXOLITINIB | CHEMBL1789941 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEXPRAMIPEXOLE | CHEMBL249420 | Small molecule | Phase 2 | ClinicalTrials.gov and TTD | 2 | 1 | 1 | Drugs and targets |
| DASATINIB | CHEMBL5416410 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DUPILUMAB | CHEMBL2108675 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RESLIZUMAB | CHEMBL2107884 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets11
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ABL1 | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Approval | https://conductscience.org/library/genes/25 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 4 | Bcr/Abl fusion protein inhibitor | Approval | https://conductscience.org/library/genes/613 | Drugs and targets |
| IL5 | Interleukin-5 | 3 | Interleukin-5 inhibitor | Approval | https://conductscience.org/library/genes/3567 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor beta | 2 | Platelet-derived growth factor receptor beta inhibitor | Approval | https://conductscience.org/library/genes/5159 | Drugs and targets |
| IL4R | Interleukin-4 receptor subunit alpha | 1 | Interleukin-4 receptor subunit alpha antagonist | Phase 2 | https://conductscience.org/library/genes/3566 | Drugs and targets |
| IL5RA | Interleukin-5 receptor subunit alpha | 1 | Interleukin-5 receptor subunit alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/3568 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| JAK3 | Tyrosine-protein kinase JAK3 | 1 | Tyrosine-protein kinase JAK3 inhibitor | Phase 2 | https://conductscience.org/library/genes/3718 | Drugs and targets |
1 to 10 of 11
See all 11 targetsTrials23
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | Phase 1/2 | 507 | 2021-06-29 | Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis | NILOTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00038675 | Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib Mesylate | Not applicable | 125 | 2022-01-04 | Chronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis | IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT02836496 | Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) | Phase 3 | 108 | 2020-02-21 | Hypereosinophilic Syndrome | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03306043 | A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 | Phase 3 | 102 | 2020-06-23 | Hypereosinophilic Syndrome | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00097370 | Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome | Phase 3 | 78 | 2015-12-15 | Hypereosinophilic Syndrome | MEPOLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00255346 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | Phase 2 | 68 | 2019-05-06 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic | DASATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02130882 | Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome | Phase 2/3 | 20 | 2022-02-08 | Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases, Leukocyte Disorders, Hypereosinophilia | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT07444567 | Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment | Phase 3 | 230 | Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES) | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT04191304 | A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) | Phase 3 | 134 | Hypereosinophilic Syndrome | BENRALIZUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT05334368 | Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial | Phase 3 | 110 | Hypereosinophilic Syndrome | DEPEMOKIMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 23
See all 23 trialsComparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| CML-CP With Prior Imatinib Only vs CML-AP With Prior Imatinib Only: Participants With (MMR) Major Molecular Response (Phase II) | 106 of 299 | 18 of 122 | 421 | NCT00109707 | Trial comparisons |
| Mepolizumab 300 mg SC vs Placebo: deaths from any cause | 1 of 54 | 0 of 54 | 108 | NCT02836496 | Trial comparisons |
| Mepolizumab 300 mg SC vs Placebo: serious adverse events | 10 of 54 | 9 of 54 | 108 | NCT02836496 | Trial comparisons |
| Drug vs Placebo: Number of Participants With 50% Reduction in Peripheral Blood Eosinophilia | 9 of 10 | 3 of 10 | 20 | NCT02130882 | Trial comparisons |
| Drug vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT02130882 | Trial comparisons |
| Drug vs Placebo: serious adverse events | 0 of 10 | 1 of 10 | 20 | NCT02130882 | Trial comparisons |
Papers from its trials26
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015691
GET https://conductscience.org/api/diseases/v1/MONDO_0015691/trials?page=2